Green factory: Plants as bioproduction platforms for recombinant proteins

Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR 72401, United States.
Biotechnology advances (Impact Factor: 9.02). 09/2011; 30(5):1171-84. DOI: 10.1016/j.biotechadv.2011.08.020
Source: PubMed


Molecular farming, long considered a promising strategy to produce valuable recombinant proteins not only for human and veterinary medicine, but also for agriculture and industry, now has some commercially available products. Various plant-based production platforms including whole-plants, aquatic plants, plant cell suspensions, and plant tissues (hairy roots) have been compared in terms of their advantages and limits. Effective recombinant strategies are summarized along with descriptions of scalable culture systems and examples of commercial progress and success.

Download full-text


Available from: Maureen Dolan, Dec 15, 2014
  • Source
    • "табак Бентхама (N. benthamiana)[69], люцерна (Medi cago sativa)[3], ряска (Lemna minor)[3]и мох (Physcomitrella patens)[70,71].[74,75]. "

    Full-text · Article · Jan 2016
  • Source
    • "However, the plant viral system requires virus inoculation to leaf or stem every time due to its transient gene expression in plant and, thus, a frequent gene mutation occurs during virus replication unlike transgenic stable expression system [75]. Thus, the choice of gene expression technique and production system should be properly pondered (Figure 1) [76]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants.
    Full-text · Article · Oct 2015
    • "Plants have long been proposed as an attractive platform for the production of recombinant proteins for human health, because of perceived safety advantages, as they do not harbour mammalian pathogens, and cost and scalability advantages, as stainless steel fermenters are not required. Results of studies conducted during the last two decades suggest that plants are cost-effective, highly scalable and safe platforms for the production of subunit vaccines, monoclonal antibodies and therapeutic proteins (Basaran and Rodr ıguez-Cerezo, 2008;Stoger et al., 2014;Tiwari et al., 2009;Twyman et al., 2012;Xu et al., 2012). In addition, plant cells are capable of performing eukaryotic post-translational modifications (PTM) of target proteins, including N-linked glycosylation, which are substantially similar to those found in mammalian cells (Gomord and Faye, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite progress in the prevention and treatment of infectious diseases, they continue to present a major threat to public health. The frequency of emerging and reemerging infections and the risk of bioterrorism warrant significant efforts towards the development of prophylactic and therapeutic countermeasures. Vaccines are the mainstay of infectious disease prophylaxis. Traditional vaccines, however, are failing to satisfy the global demand because of limited scalability of production systems, long production timelines and product safety concerns. Subunit vaccines are a highly promising alternative to traditional vaccines. Subunit vaccines, as well as monoclonal antibodies and other therapeutic proteins, can be produced in heterologous expression systems based on bacteria, yeast, insect cells or mammalian cells, in shorter times and at higher quantities, and are efficacious and safe. However, current recombinant systems have certain limitations associated with production capacity and cost. Plants are emerging as a promising platform for recombinant protein production due to time and cost efficiency, scalability, lack of harboured mammalian pathogens and possession of the machinery for eukaryotic post-translational protein modification. So far, a variety of subunit vaccines, monoclonal antibodies and therapeutic proteins (antivirals) have been produced in plants as candidate countermeasures against emerging, reemerging and bioterrorism-related infections. Many of these have been extensively evaluated in animal models and some have shown safety and immunogenicity in clinical trials. Here, we overview ongoing efforts to producing such plant-based countermeasures.
    No preview · Article · Sep 2015 · Plant Biotechnology Journal
Show more